Subtopic Deep Dive
Feline Chronic Kidney Disease
Research Guide
What is Feline Chronic Kidney Disease?
Feline Chronic Kidney Disease (CKD) is a progressive renal failure in cats staged by IRIS guidelines using serum creatinine, with research focusing on biomarkers, dietary management, and antihypertensive therapies to extend survival.
CKD represents the leading cause of death in cats over 10 years old. Studies characterize survival times by IRIS stage and identify prognostic factors like proteinuria and azotemia (Boyd et al., 2008; 201 citations; King et al., 2007; 183 citations). Recent work explores machine learning for early risk prediction and therapies like telmisartan (Bradley et al., 2019; 72 citations; Sent et al., 2015; 62 citations).
Why It Matters
Feline CKD affects up to 30-50% of cats over age 15, driving veterinary demand for diagnostics that detect disease before azotemia via SDMA biomarkers (Hall et al., 2017; 59 citations). Prognostic models from King et al. (2007; 183 citations) and Boyd et al. (2008; 201 citations) guide staging and therapy, improving survival from months to years with renin-angiotensin blockade like telmisartan (Sent et al., 2015; 62 citations). Risk factor analyses inform primary care screening to prevent progression (Greene et al., 2014; 91 citations), reducing euthanasia rates in geriatric practices.
Key Research Challenges
Early Detection Before Azotemia
Standard creatinine tests miss CKD until 75% nephron loss, delaying intervention. SDMA offers earlier detection but requires validation across populations (Hall et al., 2017). Machine learning models using routine labs predict risk but need prospective testing (Bradley et al., 2019).
Proteinuria Progression Control
Proteinuria accelerates CKD despite azotemia staging, with telmisartan outperforming benazepril in UP/C reduction (Sent et al., 2015). Hyperthyroidism treatment unmasks underlying CKD via azotemia development (Williams et al., 2010). Therapy standardization lacks feline-specific consensus beyond dogs (Brown et al., 2013).
NSAID Safety in Comorbidities
Meloxicam for DJD in aged cats shows no renal function decline despite CKD risk, challenging contraindication guidelines (Gowan et al., 2011; 108 citations). Long-term survival benefits appear in CKD cohorts (Gowan et al., 2012; 68 citations). Dose-response and monitoring protocols remain unoptimized.
Essential Papers
Survival in Cats with Naturally Occurring Chronic Kidney Disease (2000–2002)
Lauren Boyd, Catherine Langston, Karol L. Thompson et al. · 2008 · Journal of Veterinary Internal Medicine · 201 citations
Background: Duration of survival of cats with naturally occurring chronic kidney disease (CKD) is poorly characterized. Hypothesis: Stage of kidney disease based on serum creatinine concentration (...
Prognostic Factors in Cats with Chronic Kidney Disease
Jonathan N. King, Séverine Tasker, Danièlle Gunn‐Moore et al. · 2007 · Journal of Veterinary Internal Medicine · 183 citations
Background : Chronic kidney disease (CKD) is a common cause of morbidity and mortality in cats. Hypothesis : Some baseline variables are associated with shorter survival times in cats with CKD. Ani...
Survival and the Development of Azotemia after Treatment of Hyperthyroid Cats
Tim Williams, Kerry Peak, Dave C. Brodbelt et al. · 2010 · Journal of Veterinary Internal Medicine · 115 citations
The proteinuria associated with hyperthyroidism is not a mediator of progression of CKD; however, it does correlate with all cause mortality.
Consensus Recommendations for Standard Therapy of Glomerular Disease in Dogs
Scott A. Brown, Jonathan Elliott, Thierry Francey et al. · 2013 · Journal of Veterinary Internal Medicine · 113 citations
Standard therapy forms the basic foundation for care of dogs with glomerular disease, as it is herein recommended for use in all affected animals regardless of causation of the disease. Consensus r...
Retrospective Case—Control Study of the Effects of Long-Term Dosing with Meloxicam on Renal Function in Aged Cats with Degenerative Joint Disease
Richard A Gowan, Amy E Lingard, Laura Johnston et al. · 2011 · Journal of Feline Medicine and Surgery · 108 citations
Medical records (2005–2009) of a feline-only practice were searched for cats with degenerative joint disease (DJD) treated using meloxicam. DJD was diagnosed by the presence of at least two of the ...
Risk factors associated with the development of chronic kidney disease in cats evaluated at primary care veterinary hospitals
Joseph P. Greene, Sandra L. Lefebvre, Mansen Wang et al. · 2014 · Journal of the American Veterinary Medical Association · 91 citations
Abstract Objective —To identify risk factors associated with diagnosis of chronic kidney disease (CKD) in cats. Design —Retrospective case-control study. Animals —1,230 cats with a clinical diagnos...
Predicting early risk of chronic kidney disease in cats using routine clinical laboratory tests and machine learning
Richard Bradley, Ilias Tagkopoulos, Minseung Kim et al. · 2019 · Journal of Veterinary Internal Medicine · 72 citations
Abstract Background Advanced machine learning methods combined with large sets of health screening data provide opportunities for diagnostic value in human and veterinary medicine. Hypothesis/Objec...
Reading Guide
Foundational Papers
Start with Boyd et al. (2008; 201 citations) for survival by IRIS stage and King et al. (2007; 183 citations) for prognostic factors, as they establish baseline epidemiology cited in all later therapy trials.
Recent Advances
Study Bradley et al. (2019; 72 citations) for ML early detection and Sent et al. (2015; 62 citations) for telmisartan superiority, building on foundational survival data.
Core Methods
Core techniques: IRIS staging via creatinine/SDMA (Boyd 2008; Hall 2017), multivariate Cox regression for prognosis (King 2007), machine learning on EHR labs (Bradley 2019), and UP/C ratios in RCTs (Sent 2015).
How PapersFlow Helps You Research Feline Chronic Kidney Disease
Discover & Search
Research Agent uses searchPapers and exaSearch to find 250+ feline CKD papers via OpenAlex, starting with Boyd et al. (2008; 201 citations), then citationGraph reveals clusters around King et al. (2007) prognostic factors and Sent et al. (2015) telmisartan trials, while findSimilarPapers expands to SDMA biomarkers from Hall et al. (2017).
Analyze & Verify
Analysis Agent applies readPaperContent to extract survival curves from Boyd et al. (2008), verifies claims with CoVe against IRIS staging, and runs PythonAnalysis with pandas to reanalyze risk factors from Greene et al. (2014) datasets, yielding GRADE A evidence for prognostic models (King et al., 2007) and statistical p-values for meloxicam safety (Gowan et al., 2011).
Synthesize & Write
Synthesis Agent detects gaps like prospective telmisartan validation post-Sent et al. (2015), flags contradictions in NSAID risks between Gowan studies (2011, 2012), and generates exportMermaid diagrams of CKD progression pathways; Writing Agent uses latexEditText, latexSyncCitations for Boyd/King references, and latexCompile for publication-ready reviews.
Use Cases
"Analyze survival data from feline CKD cohorts using machine learning risk models."
Research Agent → searchPapers('feline CKD machine learning') → Analysis Agent → runPythonAnalysis(pandas on Bradley 2019 data) → matplotlib survival plots with risk scores output.
"Write LaTeX review on telmisartan vs benazepril in feline CKD proteinuria."
Synthesis Agent → gap detection (Sent 2015) → Writing Agent → latexEditText(draft) → latexSyncCitations(King 2007, Boyd 2008) → latexCompile(PDF with tables).
"Find code for SDMA biomarker prediction in cat kidney panels."
Research Agent → paperExtractUrls(Hall 2017) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runnable Jupyter notebook for SDMA-creatinine modeling.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ CKD papers, chaining searchPapers → citationGraph → DeepScan 7-step verification with CoVe checkpoints on survival claims (Boyd 2008). Theorizer generates hypotheses on meloxicam-CKD interactions from Gowan papers (2011, 2012), validated via runPythonAnalysis. DeepScan analyzes hyperthyroidism-CKD overlaps (Williams 2010) with GRADE grading.
Frequently Asked Questions
What defines Feline Chronic Kidney Disease?
Feline CKD is progressive renal failure staged by IRIS using serum creatinine >1.6 mg/dL, proteinuria, and SDMA elevation, leading to azotemia and uremia (Boyd et al., 2008).
What are key methods for studying feline CKD?
Methods include retrospective survival analysis (Boyd et al., 2008), prognostic modeling (King et al., 2007), machine learning on lab data (Bradley et al., 2019), and RCTs for antihypertensives like telmisartan (Sent et al., 2015).
What are the most cited papers on feline CKD?
Boyd et al. (2008; 201 citations) on natural survival by stage; King et al. (2007; 183 citations) on prognostic factors; Gowan et al. (2011; 108 citations) on meloxicam safety.
What open problems exist in feline CKD research?
Prospective validation of early ML risk models (Bradley 2019), standardized proteinuria therapies beyond telmisartan (Sent 2015), and long-term NSAID protocols in comorbid DJD-CKD (Gowan 2012).
Research Veterinary Medicine and Surgery with AI
PapersFlow provides specialized AI tools for Veterinary researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Feline Chronic Kidney Disease with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Veterinary researchers
Part of the Veterinary Medicine and Surgery Research Guide